{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:54:43Z","timestamp":1779234883727,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcyt.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T21:48:39Z","timestamp":1732312119000},"page":"350-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1645-8262","authenticated-orcid":false,"given":"Donald J.","family":"Bastin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa K.","family":"Kilgour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-5812","authenticated-orcid":false,"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Delluc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Ardolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McComb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3261-8289","authenticated-orcid":false,"given":"David","family":"Allan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-8170","authenticated-orcid":false,"given":"Tim","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.11.004_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0005","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/JCO.21.02558","article-title":"Summary of US Food and Drug Administration chimeric antigen receptor (CAR) T-cell biologics license application approvals from a statistical perspective","volume":"40","author":"Lin","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0006","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educat Book"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0007","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0010","doi-asserted-by":"crossref","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current perspectives on \u201coff-the-shelf\u201d allogeneic NK and CAR-NK cell therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0011","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0012","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0014","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1258\/la.2012.012052","article-title":"An initiative to facilitate well-informed decision-making in laboratory animal research: report of the First International Symposium on Systematic Reviews in Laboratory Animal Science","volume":"46","author":"Hooijmans","year":"2012","journal-title":"Lab Anim"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0017","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0140-6736(02)09812-4","article-title":"Systematic reviews of animal experiments","volume":"360","author":"Sandercock","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0018","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/hs1001.096009","article-title":"Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review","volume":"32","author":"Horn","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0019","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0020","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Page M, Welch VA. Cochrane handbook for systematic reviews of interventions version 6.4 (Updated August 2023). Cochrane; 2023. Available from www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.jcyt.2024.11.004_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0022","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13643-021-01824-0","article-title":"Using median survival in meta-analysis of experimental time-to-event data","volume":"10","author":"Hirst","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0023","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bjc.2012.504","article-title":"Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?","volume":"108","author":"Hirst","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0024","doi-asserted-by":"crossref","first-page":"11387","DOI":"10.18632\/oncotarget.24334","article-title":"A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models","volume":"9","author":"Jue","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2288-8-32","article-title":"The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study","volume":"8","author":"Friedrich","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"M\u00fcller","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0027","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ aggressive B-cell non\u2013Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0028","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0031","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0032","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0033","doi-asserted-by":"crossref","first-page":"626098","DOI":"10.3389\/fimmu.2021.626098","article-title":"GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0034","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jcyt.2022.02.006","article-title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma","volume":"24","author":"Schomer","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0035","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0036","doi-asserted-by":"crossref","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","article-title":"Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0037","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.2021015184","article-title":"Dual antigen\u2013targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia","volume":"140","author":"Cichocki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0038","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0039","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0040","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Intl J Cancer"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0041","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcyt.2020.06.003","article-title":"Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0042","doi-asserted-by":"crossref","first-page":"847008","DOI":"10.3389\/fimmu.2022.847008","article-title":"Genetic engineering and enrichment of human NK cells for CAR-enhanced immunotherapy of hematological malignancies","volume":"13","author":"Soldierer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0043","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.medj.2023.04.004","article-title":"A chimeric antigen receptor uniquely recognizing MICA\/B stress proteins provides an effective approach to target solid tumors","volume":"4","author":"Goulding","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407898","article-title":"Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines","volume":"7","author":"Raikar","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0045","first-page":"64","article-title":"A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia","volume":"9","author":"You","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0046","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","article-title":"2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies","volume":"12","author":"Xu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0047","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/v13071365","article-title":"Improved activity against acute myeloid leukemia with chimeric antigen receptor (CAR)-NK-92 cells designed to target CD123","volume":"13","author":"Morgan","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0049","first-page":"582","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2014655","article-title":"Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action","volume":"11","author":"Hwang","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0051","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0052","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216103","article-title":"Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia","volume":"558","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0054","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0056","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/HS9.0000000000000596","article-title":"CD38-specific chimeric antigen receptor expressing natural killer KHYG-1 cells: a proof of concept for an \u201coff the shelf\u201d therapy for multiple myeloma","volume":"5","author":"Stikvoort","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0057","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0058","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0059","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0061","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0062","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0063","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0064","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcyt.2021.10.010","article-title":"Use of CRISPR\/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: a systematic review and meta-analysis of preclinical studies","volume":"24","author":"Maganti","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2024.11.004_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/bmjos-2021-100219","article-title":"What has preclinical systematic review ever done for us?","volume":"6","author":"Russell","year":"2022","journal-title":"BMJ Open Sci"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0067","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1258\/la.2011.010121","article-title":"Systematic reviews and meta-analyses of preclinical studies: publication bias in laboratory animal experiments","volume":"45","author":"Korevaar","year":"2011","journal-title":"Lab Anim"},{"key":"10.1016\/j.jcyt.2024.11.004_bib0068","doi-asserted-by":"crossref","first-page":"e49775","DOI":"10.15252\/embr.201949775","article-title":"Why (and how) we should publish negative data","volume":"21","author":"Nimpf","year":"2020","journal-title":"EMBO Rep"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:50Z","timestamp":1762546190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1465324924009289"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}